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Abstract  
Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation 
and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal 
antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-
dose melphalan followed by autologous transplantation significantly improves progression-free 
survival; although an overall survival benefit was not observed in all trials. Moreover, follow-up of 
recent trials is still too short to show any difference in survival. In the light of these findings, novel 
agent-based induction followed by autologous transplantation is considered the standard upfront 
treatment for eligible patients (level of evidence: 1A). Post-transplant consolidation and maintenance 
treatment can further improve patient outcome (1A). The availability of several novel agents has led to 
the development of multiple combination regimens as salvage treatment options. In this context, the 
role of salvage autologous transplantation and allotransplant have not been extensively evaluated. In 
case of prolonged remission after upfront autologous transplantation, another autologous 
transplantation at relapse can be considered (2B). Patients who experience early relapse and/or have 
high-risk features have a poor prognosis and may be considered as candidates for clinical trials that - 
in young and fit patients - may also include an allograft in combination with novel agents (2B). 
Ongoing studies are evaluating the role of novel cellular therapies, such as inclusion of antibody-
based triplets and quadruplets and Chimeric Antigen Receptor-T cells: despite preliminary 
encouraging results, longer follow-up and larger patient numbers are needed before their clinical use 
can be widely recommended. 
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Introduction  
The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the 
last decades,1 with an improved median survival of 8-10 years. Multiple combinations of proteasome 
inhibitors (PIs) and immunomodulatory drugs (IMIDs) have been and are currently under evaluation in 
the transplant and non-transplant settings. Several pre-transplant inductions, and post-transplant 
novel agent-based consolidation/maintenance regimens have been investigated, although direct 
comparisons between such strategies have been rarely performed. ASCT is currently considered the 
standard of care for fit newly diagnosed MM (NDMM) patients, although remarkable results obtained in 
the non-transplant setting2,3 with novel agent-based treatment raised the question on the role of 
upfront vs delayed ASCT.  
The availability of second-generation PIs and IMIDs, monoclonal antibodies, histone deacetylase 
inhibitors, and, more recently, check-point inhibitors, and small molecules, has led to the development 
of multiple salvage options that include different permutations of these drugs. In this context, the role 
of salvage ASCT and allotransplant have not extensively been evaluated. These exciting advances 
require a critical review to delineate the merit of different induction, consolidation and maintenance 
approaches, as well as to define the role of upfront ASCT, salvage ASCT and allotransplant in the 
novel agent era. These important considerations prompted the EMN to provide guidelines to 
harmonize treatment selection. A brief overview of novel cellular therapies, which can somehow be 
considered the new frontier for transplant, are also provided. 
 
Methodology 
Clinical European Myeloma Network (EMN) experts on MM developed these recommendations based 
on published data through August 2017. Expert consensus was used to suggest recommendations in 
case of inconclusive data. Grades of recommendations were assigned using the GRADE criteria for 
grade of recommendation (Supplementary Table S1). The manuscript underwent revision in 3 rounds 
until the EMN experts reached mutual consent. 
 
 
Upfront Autologous Transplant 
The current treatment paradigm for NDMM patients eligible for ASCT consists of 4 phases, namely 
pre-transplant induction, transplant, post-transplant consolidation and maintenance.  
 
Pre-transplant Induction 
Induction treatment generally consists of 3-6 cycles with the goal to achieve rapid disease control, 
improve symptoms and allow for subsequent successful stem-cell collection. The current standard is a 
three-drug bortezomib-based combination. Doxorubicin-bortezomib-dexamethasone (PAD) proved to 
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be superior to standard chemotherapy in a randomized trial and,4 more recently, bortezomib-
cyclophosphamide-dexamethasone (VCD) was found to be non-inferior to PAD5. Improved responses 
were observed with combinations including both PIs and IMIDs. Indeed, CR rates were significantly 
higher with VTD compared with TD in 2 randomized trials (35% vs 14%, P=0.0001; 31% vs 11%, 
P<0.001).6,7 VTD vs VCD improved CR rates (13% vs 9% respectively).8 Higher CR rates were 
reported with bortezomib-dexamethasone plus the second-generation IMID lenalidomide (VRD) (23%-
48%) (Table 1).9,10 Direct, randomized comparisons of PAD vs VTD are lacking.  
Expected efficacy of a given regimen is one of the main factors to be considered in the treatment 
choice, the second factor being the expected toxicity. Infections are common events in NDMM, often 
to the underlying disease itself and to the treatment. The main issue with the use of bortezomib (in 
particular when combined with thalidomide) is the occurrence of peripheral neuropathy (PNP), which 
can be decreased substantially with subcutaneous and once-weekly administrations. The main 
concern with combinations including thalidomide or doxorubicin is the thromboembolic risk. Both PNP 
and thromboembolism appear lower when bortezomib is associated with cyclophosphamide (Table 2). 
Given that the benefit of bortezomib could be hampered by its neurological side effects, second 
generation PIs with minimal neurotoxicity demonstrated that induction treatment with ixazomib-
lenalidomide-dexamethasone (IRD) was very well tolerated (no grade 3-4 PNP, cardiac, liver or renal 
toxicities) and led to 12% CR rate.11 Carfilzomib-thalidomide-dexamethasone (KTd)12 or carfilzomib-
lenalidomide-dexamethasone (KRd)13 lead to 18-24% CR rate, although cardiovascular toxicities, 
(mainly hypertension) have been reported. 
The impact of depth of response on outcome14 provides the rationale for choosing the most effective 
induction regimen, provided the toxicity profile is acceptable. Nevertheless, only one randomized trial 
(Myeloma XI) investigated a response-adapted approach based on the sequential use of 
chemotherapeutic agents, with different modes of action in patients with a suboptimal response 
(minimal response/partial response) to thalidomide-based induction. Some 40% of patients upgraded 
their response with VCD before ASCT and significant improvement in PFS was observed (median 48 
vs 38 months, P<0.0001).15 Yet, the trial included suboptimal induction regimens (CTD and 
cyclophosphamide-lenalidomide-dexamethasone) not widely used outside the UK. The current 
standard of care is bortezomib plus IMIDs or chemotherapy, supported also by the results of two 
meta-analyses16,17 that showed the superiority of bortezomib- over non-bortezomib-
induction treatments. Thus, the impact of switching treatment - with currently much more effective 
induction regimens- still needs to be confirmed. 
 
Autologous Transplantation 
Several trials compared different chemotherapy regimens to standard high-dose melphalan 
(200mg/m2, MEL200), showing a favourable risk-benefit profile with MEL200 over Busulfan/Melphalan, 
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Idarubicin/Melphalan/Cyclophosphamide, BCNU/Etoposide/Melphalan, Melphalan 100/140 mg/m2. 
Conditioning regimens including novel agents have been evaluated so far only in single arm studies.18 
Given the efficacy and favorable toxicity profile of MEL200, this regimen remains the standard.  
Efficacy of novel-agent treatments in the non-transplant setting, together with a manageable safety 
profile and the advantage of the administration in the outpatient setting, questioned the role of 
MEL200-ASCT. Four randomized trials compared MEL200-ASCT vs novel agent-based triplets. In two 
trials, patients received Rd induction and were randomized to tandem MEL200-ASCT or oral 
lenalidomide-based chemotherapy (melphalan-prednisone-lenalidomide [MPR]/cyclophosphamide-
lenalidomide-dexamethasone [CRD]). Median PFS was significantly longer for patients randomized to 
tandem MEL200-ASCT than for those randomized to MPR (43 vs 22 months, P<0.001) or CRD (43 
months vs 28 months, P<0.001). Tandem ASCT also improved the 4-year OS rate vs MPR (82% vs 
65%, P=0.02) or CRD (86% vs 73%, P=0.004).19,20  
Two large studies compared MEL200-ASCT vs bortezomib-based regimens. MEL200-ASCT 
significantly prolonged PFS vs bortezomib-lenalidomide-dexamethasone (VRD)10 (median 50 vs 36 
months, P<0.001), and vs bortezomib-melphalan-prednisone (VMP)21 (3-year PFS 65% vs 57%, 
P=0.001). Follow-up of these two trials is still too short to show any differences in OS. 
Indeed, data confirmed that the toxicity profile was better and more manageable in the non-transplant 
arm, but no increase in toxic deaths was reported with MEL200-ASCT.10,19,20,21   
Before the introduction of novel agents, several studies showed a prolonged event-free survival (EFS) 
with double vs single ASCT.22 A subgroup analysis of one of those trials reported an improved OS 
only in patients achieving <VGPR after the first ASCT.23 A more recent integrated analysis of patient-
level data from 4 European trials demonstrated that, in patients receiving bortezomib-based induction, 
the greatest benefit with double vs single ASCT in terms of extended PFS (HR=0.41) and OS 
(HR=0.22) was seen in patients with t(4;14) and/or del(17p) and who failed CR to induction therapy.24 
Preliminary results of the EMN02 trial confirmed that patients receiving double ASCT have a superior 
PFS in comparison with patients randomized to a single ASCT (3-year PFS 74% vs 62%, P=0.05). 
The benefit was particularly evident in patients with high-risk cytogenetics (3-year PFS 65% vs 41%, 
HR 0.49, P=0.046).25  
On the contrary, the STAMINA trial showed no improvement in PFS in patients receiving double ASCT 
followed by maintenance vs single ASCT followed by VRD consolidation and lenalidomide 
maintenance. However, different induction, more effective and prolonged therapy with better disease 
control before ASCT, as well as non-adherence to the double ASCT policy in 30% of patients, can be 
a limitation of this comparative trial.26  
 
Consolidation regimens 
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Consolidation is a commonly adopted approach after transplant to improve depth of response. In 
“naïve” patients, bortezomib consolidation prolonged PFS vs no consolidation (median 27 vs 20 
months respectively; P=0.05), but no difference in OS was seen.27 In another trial, VTD consolidation 
increased the CR rate from 15% to 49% and the molecular remission rate from 3% to 18%.14 More 
recently, post ASCT consolidation with the same induction regimens was assessed. VTD increased 
the CR/nCR rate from 63% to 73%.28 Similarly, CR plus stringentCR rate increased from 47% to 50% 
after VRD.9 Preliminary results of the EMN-02 trial suggest that post-transplant VRD consolidation 
also prolongs PFS vs no consolidation (3-year PFS 65% vs 60% respectively, P=0.045);29 albeit the 
STAMINA trial did not find any improvement in PFS with single ASCT followed by VRD consolidation 
and lenalidomide maintenance vs single ASCT followed by lenalidomide maintenance; however, the 
rate of non-compliance to VRD was sizeable with 12%.26 
Similarly to induction phase, combining second-generation PIs and IMIDs is advantageous also in the 
consolidation phase, enhancing CR rates from 20% to 32% with IRD, from 31% to 64% with KTd, from 
45% to around 70% with KRD.11–13 
 
Maintenance regimens 
The optimal maintenance regimen should aim at prolonging the remission duration without affecting 
patients' quality of life. Although meta-analyses showed a reduced risk of progression (HR=0.65) and 
death (HR=0.84) with thalidomide maintenance, in the IFM and MRC IX studies, patients with 
unfavorable cytogenetics did not benefit from this approach.30,31 In addition, grade 3-4 PNP (7-19%) 
and treatment discontinuation due to PNP limit the long-term use of thalidomide. 
Bortezomib maintenance seems to be a better option: a landmark analysis of the HOVON-65/GMMG-
HD4 trial showed that bortezomib maintenance significantly reduced the risk of progression (P=0.04) 
and death (P=0.05) as compared with thalidomide, with a similar rate of grade 3-4 PNP (5% vs 8%).4 
Results of this trial also suggest that pre-transplant bortezomib induction followed by bortezomib 
maintenance significantly reduces the high-risk impact of del(17p) and renal impairment on survival.32 
More recently, longer PFS was reported also with the bortezomib-thalidomide combination vs 
thalidomide alone.33 
Lenalidomide is another valid strategy for long-term treatment, with limited neurotoxicity: 4 trials 
subsequently evaluated lenalidomide maintenance after ASCT,19,34–36 showing a consistent PFS 
benefit for lenalidomide vs no maintenance (HR range 0.46-0.50). A meta-analysis of the first three 
randomized trials reported a significant increase also in OS (7-year OS 62% vs 50%, HR 0.75; 
P=.001) across all subgroups analyzed with the exception of patients with high-risk cytogenetics. In 
the MRC trial, a significant PFS benefit was maintained also in patients with high-risk cytogenetics, but 
no data on OS are currently available. Main grade 3-4 toxicities were neutropenia (23-51%), and 
infections (6-13%).19,34,35 Although second primary malignancies (SPMs) were higher with 
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lenalidomide maintenance vs control (hematologic SPM, 6.1% vs 2.8%; solid tumor SPM, 7.3% vs 
4.2%),37 the OS benefit outweighed the SPM risk.  
Recommendations: In NDMM patients eligible for high-dose therapy and ASCT, sequential treatment 
including novel agent-based induction, upfront transplant, post-transplant bortezomib plus IMiDs 
consolidation and maintenance is recommended (1A; Figure 1). Treatment choice should be based on 
evidence supporting a specific treatment, and on a thorough evaluation of patient characteristics, 
toxicity of the expected regimens and availability of drugs in the specific countries (Table 3).  
 
Special considerations 
Currently, selection criteria for high-dose therapy include age and comorbidities. However, a definite 
age cut off is suboptimal, rather than assessment of patients’ biological age, comorbidities, fitness and 
frailty/comorbidity scores. Besides age, the performance status, cardiac, pulmonary, hepatic and renal 
functions should be considered to better evaluate the risk-benefit ratio of transplant for each patient, 
and specific risk-assessment models, such as myeloma comorbidity index (MCI) and/or Hematopoietic 
cell transplantation comorbidity index (HCT-CI) should be used to better modulate the dose of 
chemotherapy.38–40 Specific considerations refer to patients with renal failure (RF) and elderly patients.  
 
Renal failure (RF) 
Around 20% of patients present at diagnosis with creatinine >2mg/dL. Bortezomib-based regimens 
remain the cornerstone for the management of RF. Indeed, higher response rates were reported with 
PAD vs VAD induction in patients with RF (81% vs 63%, p=0.31).41 In dialysis patients, bortezomib-
based induction vs conventional chemotherapy significantly increased pre-transplant (83% vs 36%, P= 
0.02) and post-transplant overall response rate (100% vs 58%, P=0.01). Prolonged EFS and a trend 
towards a decreased time on hemodialysis (6 vs 17 months) was also reported.42 Combination of 
bortezomib with high cut-off hemodialysis led to prompt and remarkable responses.43 RF does not 
appear to affect the quality of stem cell collection.44 Persistent RF or dialysis are not contraindications 
to high-dose therapy and ASCT,45 since patients may improve renal function after ASCT. 
Nevertheless, the rate of treatment-related mortality (TRM) ranges from 0 to 29% in different reports 
and with different melphalan doses.42,44 Thus, due to the potentially higher toxicity of 200mg/m2, dose 
reductions are mandatory particularly in dialysis patients. Other suggested reductions in case of 
impaired organ function are reported in Supplementary Table S2. Of note, a recent large retrospective 
analysis showed no significant differences in the 5-year PFS and OS between transplant patients with 
normal, moderate (GFR 30-60 ml/min/1.73 m2) and severe RF (GFR <30). For patients with moderate 
RF, 5-year PFS was 18% with melphalan 140mg/m2, and 46% with melphalan 200mg/m2 (p=0.009); 5-
year OS was 67% and 68%, respectively (p=0.52). In patients with severe RF (GFR <30) no 
differences in 5-year PFS and OS were reported between groups. Relapse remained the primary 
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cause of death in all patient subgroups.46 In this report, 85% patients achieved dialysis independence 
post-ASCT even though, in previous case-series, rate of dialysis independency varied from 6 to 
25%.44 
Of interest, around 10% of younger patients may achieve long-lasting responses, which makes them 
potential candidates for renal transplantation. However, many issues, including donor availability, the 
immunosuppression risks and the possible disease relapse on the xenograft, need to be considered. 
Thus, patients with low-risk disease and with negative MRD might be considered eligible for 
transplantation in the future but currently, due to limited data, no recommendations can be made.44 
 
Transplant in the elderly 
Aging is associated with reduced organ function and drug metabolism, with potentially increased 
toxicity and TRM. The potential increase in toxicity has led to the evaluation of reduced doses of 
melphalan (100-140mg/m2) conditioning. Many studies, mostly retrospective, observational or registry-
based, provided encouraging results with ASCT in patients >65 years, with TRM <3-4%.47 No 
differences in TRM (1%) were reported with tandem melphalan 140mg/m2 in patients aged 60-65 vs 
65-70 in the large DSMM II trial.48 Interestingly, a recent study found that ASCT-TRM was 0% with 
either melphalan 140mg/m2 or 200mg/m2, which may partly be due to improvements in supportive 
therapy and better patient selection.49 A recent EBMT study confirms increased utilization and safety 
of ASCT with improved post-transplant survival, particularly in elderly MM patients.50 
Former analysis of non-ASCT treatment vs ASCT in the elderly (65-75 years) compared thalidomide 
based chemotherapy (MPT) vs reduced-intensity (melphalan 100mg/m2) ASCT in patients aged 65-75 
years in the IFM9906 trial. MPT significantly reduced the risk of progression (HR 0.54, P=0.0002)51 
and death (HR 0.69; P=0.027), but the lack of novel agents in the pre-ASCT induction and the low 
melphalan dosing can be a limitation to the study. The rate of toxic deaths was also higher (5%) during 
induction in the ASCT arm. Afterwards, other prospective trials evaluated a sequential approach 
including novel agent based induction, consolidation and maintenance. One study showed that PAD 
induction, followed by MEL100-ASCT, lenalidomide-prednisone consolidation and lenalidomide 
maintenance was highly efficacious (VGPR rate 82%; 5-year OS 63%) and feasible, in particular for 
patients <70 years, who reported a significantly lower rate of TRM in comparison with elderly patients 
(5% vs 19%).52 A recent report suggests that bortezomib consolidation after ASCT may determine 
clinical outcomes in older patients, who may have been less heavily pre-treated, as in younger ones 
treated with standard doses of melphalan.53 The phase III DSMM XIII trial compared continuous Rd vs 
Rd induction followed by tandem melphalan 140mg/m2-ASCT and lenalidomide maintenance. Results 
of the planned interim analysis showed a 3-year-survival rate of 75% for all patients. A longer follow-
up is needed to evaluate the potential advantages and disadvantages of combining lenalidomide with 
high-dose melphalan-ASCT as compared with continuous Rd.54 
9 
Recommendations: Biological age rather than chronological age, PS, and organ function should be 
considered to better evaluate the risk-benefit ratio of transplant for each patient (1B, Figure 2). 
Objective risk-assessment scores, such as revised-myeloma comorbidity index (R-MCI) and/or 
Hematopoietic cell transplantation comorbidity index (HCT-CI) can be used to define the appropriate 
dose of chemotherapy38–40 (1B, Table 4). 
 
Transplant at relapse 
Upfront vs rescue transplant 
In the past, several randomized trials confirmed the PFS benefit with early ASCT as compared with 
chemotherapy. In three randomized studies, OS was similar whether ASCT was performed early or at 
first relapse. Despite similar OS, early ASCT improved the average time without symptoms and 
reduced treatment-related toxicities in one trial.55 However, at the time of these trials, most novel 
agents were not available. Based on the impressive results of novel agent-based treatments in the 
non-transplant setting, the option of delaying ASCT until first relapse was again reconsidered.2,3,56 In 
all the recent randomized phase III trial comparing ASCT vs novel agent-based therapies, patients 
who did not receive ASCT upfront were recommended to receive it at first relapse. A pooled analysis 
including the GIMEMA and the EMN441 trials showed that only 53% of patients eligible for Mel200-
ASCT at diagnosis actually received ASCT at first relapse. Upfront MEL200-ASCT significantly 
improved not only PFS1, but also PFS2 (4-year: 71% vs 54%, HR 0.53, p<0.001) and OS (4-year: 
84% vs 70%, HR 0.51, P<0.001) as compared with oral chemotherapy plus lenalidomide.57 Of note, in 
the IFM2009 trial, where up to 79% of patients treated with lenalidomide plus bortezomib upfront were 
rescued with ASCT at relapse, no differences in OS were noticed.10  
 
Transplant in patients relapsing after prior autograft 
Multiple retrospective analyses showed that chemo-sensitivity and remission duration after first ASCT 
are the most important prognostic factors for long-term disease control after salvage ASCT.58,59 Most 
reports also highlighted the impact of the number of prior therapies on outcome, suggesting that 
salvage ASCT should be part of the initial salvage strategies, rather than be offered to patients who 
have failed multiple therapy lines. A retrospective analysis on 1061 patients showed a significantly 
longer median survival for patients who received salvage ASCT (4 years) vs those who received 
salvage IMIDs/PIs and no ASCT (3.3 years), and those who received conventional chemotherapy (2.5 
years).60 A limitation of this analysis is a possible selection bias as patients treated with ASCT may 
have been in better clinical condition if compared with those who did not. Nevertheless, the phase III 
multicenter randomized Myeloma X trial showed a significant advantage in time to progression (19 vs 
11 months, P<0.001) and OS (67 vs 52 months, p=0.022) in patients relapsing after a previous ASCT, 
and then randomized to receive either a second ASCT or oral cyclophosphamide.61 The limitation of 
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this trials however is that, even though all patients were re-induced with PAD prior to randomization, 
the control arm with cyclophosphamide alone can now be considered suboptimal. A recent 
retrospective EBMT analysis showed that even a third ASCT at relapse may be feasible, with more 
than 80% of patients achieving at least a PR, although with increased non-relapse mortality. 
Particularly in severely cytopenic patients where hematologic toxicity of conventional treatment may 
be prohibitive, ASCT may be a rescue option. The option of a third ASCT mostly followed a previous 
upfront approach with tandem ASCT; some patients received a first ASCT followed by a second ASCT 
at second relapse and a third ASCT at subsequent relapse. The first scenario resulted in better results 
with a median OS of more than 4 years if the relapse occurred after more than 3 years after the 
upfront tandem ASCT.62  
Recommendations: Upfront ASCT remains the standard option for patients eligible for HDT (1A, 
Figure 1). A second transplant at relapse should be considered after a minimal duration of remission 
of 18 months after a first ASCT (1B); this cut-off could be extended to 24 months in the context of 
novel induction/maintenance.63 A second ASCT should be offered as a first salvage therapy rather 
than after failing multiple lines (2B). Novel-agent based induction and consolidation-maintenance 
should be adopted also in the elderly (1A). 
 
Allotransplant 
When and in which patients 
A review of approximately 3000 ASCTs and allo-SCTs, performed in the US between 2007 and 2009, 
showed that, overall, 47.1% of ASCTs and only 3.6% of allo-SCTs were performed in MM patients.64 
However, the number of allo-SCTs for MM in Europe steadily increased from 1990 to 2012.65 Before 
new drugs became readily available almost 20 years ago, in a series of "biologically" randomized 
prospective studies, the concept of splitting myeloablation and graft-vs-myeloma (GVM) by a tandem 
approach with a standard ASCT followed by a non-myeloablative allo-SCT, from a matched sibling or 
an unrelated donor, was explored in NDMM (Table 5).66–76 Results were discordant, and this was likely 
due to differences in study design, target population and post-transplant immuno-suppression (Table 
3). Moreover, only at long-term follow-up differences in clinical outcomes between arms were 
observed.73,74. Of note, at that time, most studies could not include new drugs either at induction or as 
post allo-SCT maintenance/consolidation. 
Partly due to the conflicting results and to the introduction of new drugs, allo-SCT has rather been 
used in recent years as a salvage strategy at relapse, often not in the context of clinical trials. Most 
reports were single-institution or registry analyses. Only a few comparative studies have been 
conducted, and those are limited by their retrospective nature and/or small patient cohorts (Table 6). In 
a recent EBMT report65 on 7333 MM patients who underwent allo-SCT between 1990 and 2012, 3405 
had received allo-SCT as a second line or beyond regimen: this report showed that 25% of the patient 
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cohort who received allo-SCT more than 8 months from the first ASCT survived at 10 years, 
suggesting that cure may have been reached through a GVM mechanism in some patients. Another 
retrospective EBMT analysis identified patient and donor CMV seronegativity as the key prognostic 
factor for better outcome after allo-SCT in relapsed patients.77 One prospective study78 concluded that, 
with well-matched donors, the non-relapse mortality was 10%, and about 20% of patients achieved 
long-term disease free survival. The high response rates seen after DLI administration are additional 
evidence for the GVM. 
All together, these studies showed the feasibility of allo-SCT in relapsed MM; however, given the 
heterogeneous patient cohorts and differences in conditioning regimens and supportive care, its real 
role and curative potential has not been clearly established. Both reduced-intensity and myeloablative 
conditionings have been successfully used, and so far, the choice should be based on center policy 
and patients comorbidities. 
Considering the lack of effective therapy for high-risk patients carrying del(17p), gain(1q), t(4;14) and 
t(14;16) abnormalities, new treatment modalities should be sought in this patient subset. The negative 
prognostic impact of high-risk cytogenetics appeared to be partly neutralized by GVM in two recent 
studies. Kröger et al. did not observe significant differences in PFS between del17p13 and/or t(4;14)-
harboring patients and those without these genetic abnormalities after a median follow-up of 6 years 
(24% vs 30%; P=0.70). Depth of remission had a remarkable impact on 5-year PFS: 17% for PR, 41% 
for CR, 57% for molecular CR, and 85% for sustained molecular CR.79 A French trial also showed no 
differences in clinical outcomes between t(4;14) and non-t(4;14) patients. Moreover, the 3-year 
progression rate did not exceed 45% in patient with del(17p).80 Taken together, these findings raise the 
question whether high-risk patients who usually experience poor outcomes and easily develop 
resistance to novel agents would benefit from allo-SCT earlier in the course of the disease. 
 
Evidence of graft vs myeloma 
Response to DLIs is often seen as proof of GVM. However, the prolonged post-relapse survival 
reported after tandem auto-allo-SCT upfront suggests an important synergy between novel agents and 
GVM.73,74 In several reports, DLIs have been used as salvage treatment. Beitinjaneh et al.81 reported 
on 23/162 patients with MM receiving DLI post allo-SCT for residual or relapsed disease: 22% 
achieved >VGPR, with a median duration of 21.8 months. Similarly, an analysis of EBMT registry data 
reported a response rate of 63% in 70 patients when DLI was given preemptively and 52% when given 
at relapse.82 Ladetto et al. reported a gradual reduction of residual disease with longer follow up. 
Minimal residual disease negativity, detected by molecular methods, remained low up to 3 months 
post alloSCT, then increased up to 44% at 6 and 47% at 12 months.83 Importantly, these patients did 
not receive any maintenance/consolidation treatment. These findings also compared favorably with 
the molecular analysis conducted by the same group in patients undergoing autografting and VTD 
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consolidation.14 Finally, although not univocal, many trials reported a favorable association between 
development of chronic GVHD and prolonged PFS and OS,84,85 again supporting a GVM effect. 
 
Novel agents and graft-vs-myeloma 
Although the introduction of “new drugs” has made allografting a less attractive treatment option 
because of its toxicity, the mechanisms of action of new drugs and immune-mediated GVM effects are 
by no means mutually exclusive.73,74 Given that one of the most important predictors of survival is the 
response at the time of transplant and the major limitation remains disease recurrence as for all other 
treatments, the new anti-MM drugs may strongly improve outcomes of allo-SCT. Moreover, the 
concept of maintenance treatment was also recently introduced in the setting of allografting. 
Bortezomib has been used before allo-SCT and early after allo-SCT to eliminate residual disease and 
to decrease graft-vs-host disease (GVHD) incidence and severity based on its presumed 
immunomodulator potency in at least two prospective studies86,87 on 16 and 12 high-risk MM patients, 
respectively. Both trials proved feasible and safe, and, based on these results, the expert panel agrees 
that confirmatory larger studies should be designed. 
Lenalidomide is also of interest in the allo-SCT setting though caution is mandatory because of the 
risk of GVHD flares if given too shortly after transplant. Three trials86,88,89 demonstrated that post allo-
SCT lenalidomide maintenance was feasible and contributed to further reduce MM tumor burden with 
PFS rates of 52% at 3 years;88 63% at 3 years,89 and 60% at 2 years90. GVHD flares were observed in 
28% to 47% of cases. 
 
Update on current studies 
At the 2016 American Society of Hematology meeting (December 2016), reports on myeloma and allo-
SCT mainly focused on interactions of new drugs and GVM, and three groups unanimously reported 
remarkable responses to new drugs used as post-allo-SCT salvage, clearly showing a synergism with 
GVM. A retrospective study comparing OS after relapse from upfront auto-allo (n=178) vs double auto-
SCT (n=404) was conducted through the CIBMTR (Center for International Blood and Marrow 
Transplant Research) registry.91 Despite a higher risk population (46% of early relapse from 2nd SCT 
vs 26%) in the allo-SCT group, long-term reduction in post-relapse mortality (HR for death in auto-
auto-SCT=1.55; p=0.0052) was observed. This was clearly attributable to improved response to 
salvage therapy due to the donor derived immunologic milieu that potentiated the immune effects of 
new agents. Similarly, Giaccone et al showed prolonged OS from 1st relapse post tandem auto-allo-
SCT compared to double auto-SCT (89.8 months vs 23.5 months, p=0.009).92 López-Corral et al 
reported similar pre-transplant and post-transplant response rates and durability of response achieved 
with new drugs before and after allo-SCT: responses post allo-SCT were at least similar in proportion 
and durability to those observed in the pre-transplant setting, which is in contrast to the usual course 
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of the disease outside the allo-SCT setting.93 Another study reported on 18 high-risk MM patients who 
received upfront auto-SCT followed by RIC allo-SCT and bortezomib as maintenance, which was 
overall well tolerated, although 4/18 had asymptomatic EBV reactivation. Depth of response improved 
after bortezomib, with 67% of patients in CR or stringent CR.94 
Daratumumab has also demonstrated encouraging efficacy in 10 heavily pretreated 
relapsed/refractory patients after allo-SCT. Safety profile was good with in the majority of cases non-
severe AEs mostly after the first infusion; 5/9 evaluable patients responded and all responding 
patients maintained their responses 7, 14, 35, 54 and 84 days after the first administration.95 Cook et 
al monitored immune biomarkers with the use of lenalidomide after T depleted RIC-alloSCT, showing 
that the agent allowed sustained quantitative and functional reconstitution of donor immune 
homeostasis.96 McKiernan et al97 reported of a long-term comparison in patients receiving allo-SCT as 
upfront consolidation (n=75) or as salvage therapy (n=43). The 10-year OS for patients who received 
allo-SCT as salvage was 36% vs 68% for the consolidation group (p=0.0007). Of note, having 
undergone ≥2 prior auto-SCTs predicted for a higher risk of mortality (p=0.05). Chronic GVHD was 
favorable, associated with a 36% improvement in OS (p=0.0008).  
Recommendations: Previous studies that did not include novel agents reported long-term molecular 
remissions, and possibly cure, in patient subsets. Well-designed prospective trials combining “graft-
vs.-myeloma” and new drugs may become urgent in young high-risk/ultra high-risk patients whose 
treatment remains an unmet clinical need. However, there are no current data that support an upfront 
allograft. A clinical indication/recommendation may also become “early relapse” after first-line 
treatment (including the new PI and IMIDs) which identifies patients at very poor prognosis 
independent of other prognostic factors (Table 7). Re-induction to obtain tumor shrinking using novel 
drugs as bridge to transplant is highly recommended/mandatory in this setting.98 Novel agent-based 
combinations should be considered also in association with DLI in case of relapse after allogeneic 
transplant. 
 
Future developments 
Treatment for MM has undergone a dramatic improvement in the past decade given the considerable 
advances in the understanding of the disease pathogenesis and numerous novel drugs and 
combinations being approved for the disease. Despite the development of novel agents which target 
not only MM cells but also the microenvironment,99 the prognosis of patients with early 
relapsed/refractory MM remains poor. Thus, new therapeutic modalities are urgently needed to 
overcome resistance to current therapies. Several immunotherapies have recently been proposed, 
which - among others - include monoclonal antibodies, antibody-drug conjugates, chimeric antigen 
receptor T-cell therapy (CAR-T cells), tumor vaccines and immune checkpoint inhibitors.100 Preliminary 
results observed in patients with B cell hematologic malignancies with infusion of T cells genetically 
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modified to express synthetic chimeric antigen receptors (CARs) against the lineage-specific surface 
antigen CD19 were impressive. T cells engineered with an anti-CD19 CAR induced CR also in a 
patient with MM.101 Recently, a number of other CAR-T cells have been designed to target surface 
antigens expressed by MM cells and include CD38,102 CD138,103 CD269, the B cell maturation antigen 
(BCMA),104 κ light chains,105 CS1 (CD319)106 and CD44v6.107 However, despite their efficacy, CAR-T 
cells have raised many concerns on their short- and long-term toxicities, in particular the development 
of life-threatening cytokine release syndrome (CRS) and prolonged aplasia of the healthy 
counterparts.108 Genetic modifications of cells belonging to the innate immune system such as natural 
killer (NK) cells are also being explored, and modification of the human NK cell lines NKL and NK-92 
with a lentiviral vector encoding for CS1 and CD138 CARs has proven feasible.109 However, several 
steps to optimize and validate CAR-modified NK cells have to be undertaken before their wider clinical 
use becomes feasible. 
 
Conclusions  
The changes in the treatment paradigm for MM patients in the last two decades dramatically improved 
survival. Clearly, results of the most recently published trials confirm the role of ASCT in the era of 
novel agents, with new drugs administered both in the pre-transplant and post-transplant phases. The 
expert panel emphasizes that present clinical research should balance between treatment efficacy and 
quality of life, identify the optimal sequencing of treatment, the appropriate tools for patient selection, 
evaluate costs of prolonged novel-agent application vs transplant remission efficacy, treatment-free 
intervals, and it should understand how to best induce long-term remission.110 In the future, objective, 
prospective and proficiently performed fitness tools may prove to be of benefit before intensive 
treatment is started, especially since fitness assessments made by patients and physicians are not as 
objective as fitness evaluations derived from well-defined tests and scores. Future randomized studies 
will also need to evaluate the role of ASCT as salvage treatment in the context of the novel 
combinations currently available as salvage options. 
The trend in survival improvement is likely to continue in the future with new classes of drugs (such as 
MoAb) and second-generation PIs and IMIDs moving in the upfront setting. If most patients can now 
expect a long-term disease control, the optimal definition of high-risk disease and the specific 
treatment for these patients remains a major challenge. Based on the available data, the opinion of the 
expert committee is that allotransplant in combination with novel agents might be considered in the 
context of clinical trials for high-risk patients who are willing to accept the TRM for a chance of a better 
long-term survival. Moreover, cellular therapies, now still highly experimental, should be optimized, 
made broader available and payable to be included in our treatment armamentarium. 
 
15 
Acknowledgments: This work is supported by the Deutsche Krebshilfe (grants 1095969 and 111424 
to ME and RW). The expert panel thanks all the investigators of the EMN group in the different 
countries for their support. 
 
Disclosures: FG has received honoraria from Takeda, Amgen, Celgene, Janssen, BMS, and served 
on the advisory board for Takeda, Seattle Genetics, Celgene, Roche . ET has received honoraria from 
Amgen, Celgene/Genesis, Janssen, Novartis, BMS, Takeda and GSK, research support from Amgen, 
Takeda, Janssen, he is a Steering Committee Member of Amgen, Takeda and a DMC member of 
Celgene. HWA has received consultancy fees from Chugai and Takeda. JC has served on the 
advisory board for Amgen and Janssen, and received research funding from Celgene. NVDD has 
received research support from Janssen Pharmaceuticals, Celgene, BMS, AMGEN, Novartis, and 
served on the advisory board for Janssen Pharmaceuticals, Celgene, BMS, AMGEN, Novartis. SO 
has received Honoraria from Takeda and Celgene. EZ has received honoraria from and served on the 
advisory board for Celgene, Janssen, Amgen, BMS. RH has received honoraria from Takeda, Amgen, 
Janssen, Novartis and Celgene. HL has received honoraria from Amgen, Takeda, Celgene, Janssen, 
and research support from Amgen and Takeda. HE has served on the advisory board for, and 
received honoraria and research support from, Janssen and Celgene, and he is a member of their 
speaker's bureau, he has received honoraria from Amgen and Novartis and he is a member of their 
speaker's bureau. MD has received honoraria from and served on the advisory board for Celgene, 
Amgen, Janssen, Takeda. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, 
Novartis, Abbvie, BMS, research funding from Celgene, Janssen, Amgen, BMS, Mundipharma, 
Novartis, Sanofi. NK has received research grant from Celgene, honoraria for lectures from Amgen, 
Sanofi, Janssen. MC has received honoraria from Janssen, Amgen, BMS, and Celgene. HG has 
received research support from Celgene, Janssen, Chugai, Novartis, BMS, Millenium, Morphosys, 
served on the advisory board for Janssen, Celgene, Novartis, Onyx, Amgen Takeda, BMS, speaker’s 
bureaus for  Celgene, Janssen, Novartis, Chugai, Onyx, Millenium. PS has received honoraria from 
Amgen, Celgene, Janssen, Karyopharm, BMS and research support from Amgen, Celgene, Janssen, 
Karyopharm.   
16 
References 
1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early 
mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.  
2. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of 
multiple myeloma. N Engl J Med. 2008;359(9):906–917.  
3. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible 
patients with myeloma. N Engl J Med. 2014;371(10):906–917.  
4. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients 
with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin 
Oncol. 2012;30(24):2946–2955.  
5. Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus 
bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–1729.  
6. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction 
pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 
2012;120(8):1589–1596.  
7. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide 
plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell 
transplantation in newly diagnosed multiple myeloma: a randomised phase 3. Lancet. 2010;376(9758):2075–2085.  
8. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of 
the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–2574.  
9. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, 
and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients 
with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712–
2717.  
10. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for 
Myeloma. N Engl J Med. 2017;376(14):1311–1320.  
11. Moreau P, Hulin C, Caillot D, et al. Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after 
Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed 
Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone . Blood. 2016;128(22):674.  
12. Wester R, van der Holt B, Asselbergs E, et al. Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose 
Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, 
the Carthadex Trial. Blood. 2016;128(22):1141.  
13. Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline Therapy with Carfilzomib, Lenalidomide, and 
Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and 
Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the 
Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study. Blood. 2016;128(22):1142.  
14. Ferrero S, Ladetto M, Drandi D, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving 
VTD consolidation after ASCT: MRD kinetics’ impact on survival. Leukemia. 2015;29(3):689–695.  
15. Jackson GH, Davies FE, Pawlyn C, et al. Response Adapted Induction Treatment Improves Outcomes for Myeloma 
Patients; Results of the Phase III Myeloma XI Study. Blood. 2016;128(22):244.  
16. Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment 
before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis 
of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–3287.  
17 
17. Nooka AK, Kaufman JL, Behera M, et al. Bortezomib-containing induction regimens in transplant-eligible myeloma 
patients. Cancer. 2013;119(23):4119–4128.  
18. Shah N, Callander N, Ganguly S, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines 
from the American Society for Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 2015;21(7):1155–
1166.  
19. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N 
Engl J Med. 2014;371(10):895–905.  
20. Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by 
lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, 
multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629.  
21. Cavo M, Beksac M, Dimopoulos MA, et al. Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus 
Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III 
Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood. 2016;128(22):673.  
22. Fermand JP, Alberti C, Marolleau JP. Single versus tandem high dose therapy (HDT) supported with autologous 
blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: Results of a two by two designed 
randomized trial in 230 young patients with multiple myeloma (MM). Hematol J. 2003;4(Suppl 1):S59.  
23. Attal M, Harousseau J-L, Facon T, et al. Single versus Double Autologous Stem-Cell Transplantation for Multiple 
Myeloma. N Engl J Med. 2003;349(26):2495–2502.  
24. Cavo M, Salwender H, Rosiñol L, et al. Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-
Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase 
European III Studies. Blood. 2013;122(21):767.  
25. Cavo M, Petrucci MT, Di Raimondo F, et al. Upfront Single Versus Double Autologous Stem Cell Transplantation for 
Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network 
(EMN02/HO95 MM Trial). Blood. 2016;128(22):991.  
26. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Comparison of Autologous Hematopoietic Cell Transplant 
(autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), 
Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front. Blood. 
2016;128(22):LBA-1.  
27. Mellqvist U-H, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in 
multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647–4654.  
28. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-
dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with 
newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.  
29. Sonneveld P, Beksac M, van der Holt B, et al. Consolidation Followed By Maintenance Therapy Versus Maintenance 
Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study 
of the European Myeloma Network (EMN02/HO95 MM Trial). ASH. 2016;128(22):242.  
30. Attal M, Harousseau J-L, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with 
multiple myeloma. Blood. 2006;108(10):3289–3294.  
31. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC 
Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.  
32. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term 
results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2017 Jul 4. [Epub ahead of print]  
33. Rosiñol L, Oriol A, Teruel AI, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for 
multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017;31(9):1922-1927.  
18 
34. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple 
Myeloma. N Engl J Med. 2012;366(19):1782–1791.  
35. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N 
Engl J Med. 2012;366(19):1770–1781.  
36. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma 
Patients of All Ages; Results of the Phase III Myeloma XI Study. Blood. 2016;128(22):1143.  
37. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell 
Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35(29):3279–3289.  
38. Saad A, Mahindra A, Zhang M-J, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after 
autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402–
408.e1.  
39. Labonté L, Iqbal T, Zaidi MA, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity 
following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 
2008;14(9):1039–1044.  
40. Engelhardt M, Domm A-S, Dold SM, et al. A concise revised myeloma comorbidity Index as a valid prognostic 
instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910-921.  
41. Scheid C, Sonneveld P, Schmidt-Wolf IGH, et al. Bortezomib before and after autologous stem cell transplantation 
overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup 
analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–154.  
42. Breitkreutz I, Heiss C, Perne A, et al. Bortezomib improves outcome after SCT in multiple myeloma patients with 
end-stage renal failure. Bone Marrow Transplant. 2014;49(11):1371–1375.  
43. Zannetti BA, Zamagni E, Santostefano M, et al. Bortezomib-based therapy combined with high cut-off hemodialysis 
is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 
2015;90(7):647–652.  
44. Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA. Current treatments for renal failure due to multiple 
myeloma. Expert Opin Pharmacother. 2016;17(16):2165–2177.  
45. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the 
Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34(13):1544–1557.  
46. Mahindra A, Hari P, Fraser R, et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with 
renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow 
Transplant. 2017 Sep 18. [Epub ahead of print] 
47. Ozaki S, Shimizu K. Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, 
and future. Biomed Res Int. 2014;2014:394792.  
48. Straka C, Liebisch P, Salwender H, et al. Autotransplant with and without induction chemotherapy in older multiple 
myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101(11):1398–1406.  
49. Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly 
multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101(11):1390–1397.  
50. Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in 
Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 
2015;50(2):209–215.  
51. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone 
alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): 
a randomised trial. Lancet. 2007;370(9594):1209–1218.  
52. Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide 
19 
consolidation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376–1383.  
53. Straka C, Knop S, Vogel M, et al. Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome 
for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple 
Myeloma. Blood. 2016;128(22):516.  
54. Straka C, Schaefer-Eckart K, Bassermann F, et al. Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously 
Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned 
Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Mult. Blood. 
2014;124(21):3969.  
55. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell 
transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized 
clinical trial. Blood. 1998;92(9):3131–3136.  
56. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus 
chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized 
controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183–196.  
57. Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed 
young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-1734. 
58. Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second Autologous Stem Cell Transplantation as Salvage Therapy 
for Multiple Myeloma: Impact on Progression-Free and Overall Survival. Biol Blood Marrow Transplant. 
2012;18(5):773–779.  
59. Auner HW, Szydlo R, Rone A, et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or 
progressing after up-front autologous transplantation. Leuk Lymphoma. 2013;54(10):2200–2204.  
60. Grövdal M, Nahi H, Gahrton G, et al. Autologous stem cell transplantation versus novel drugs or conventional 
chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 
2015;50(6):808–812.  
61. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival 
in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a 
randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3(7):e340–e351.  
62. Garderet L, Iacobelli S, van Biezen A, et al. Outcome of Third Salvage Autologous Stem Cell Transplantation in 
Multiple Myeloma. Blood. 2016;128(22):993.  
63. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up†. Ann. Oncol. 2017;28(suppl_4):iv52-iv61.  
64. Kumar S, Zhang M-J, Li P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR 
analysis. Blood. 2011;118(7):1979–1988.  
65. Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: 
trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 
2016;30(10):2047–2054.  
66. Bruno B, Rotta M, Patriarca F, et al. A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. N 
Engl J Med. 2007;356(11):1110–1120.  
67. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by 
dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk 
de novo multiple myeloma. Blood. 2006;107(9):3474–3480.  
68. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing 
nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 
2008;112(9):3914–3915.  
20 
69. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation 
versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple 
myeloma. Blood. 2008;112(9):3591–3593.  
70. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic 
or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 
biological assignment trial. Lancet Oncol. 2011;12(13):1195–1203.  
71. Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma 
patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219–6225.  
72. Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-
Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. J Clin Oncol. 
2011;29(22):3016–3022.  
73. Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with 
autografting for newly diagnosed myeloma. Blood. 2011;117(24):6721–6727.  
74. Gahrton G, Iacobelli S, Björkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs 
autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 
2013;121(25):5055–5063.  
75. Bruno B, Sorasio R, Patriarca F, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative 
conditioning for patients with high-risk multiple myeloma. Eur J Haematol. 2007;78(4):330–337.  
76. Georges GE, Maris MB, Maloney DG, et al. Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation 
to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 
2007;13(4):423–432.  
77. Auner HW, Szydlo R, van Biezen A, et al. Reduced intensity-conditioned allogeneic stem cell transplantation for 
multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood 
and Marrow Transplantation. Bone Marrow Transplant. 2013;48(11):1395–1400.  
78. Kröger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for 
patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010;148(2):323–331.  
79. Kröger N, Badbaran A, Zabelina T, et al. Impact of High-Risk Cytogenetics and Achievement of Molecular Remission 
on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple 
Myeloma. Biol Blood Marrow Transplant. 2013;19(3):398–404.  
80. Roos-Weil D, Moreau P, Avet-Loiseau H, et al. Impact of genetic abnormalities after allogeneic stem cell 
transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. 
Haematologica. 2011;96(10):1504–1511.  
81. Beitinjaneh AM, Saliba R, Bashir Q, et al. Durable responses after donor lymphocyte infusion for patients with 
residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk. Lymphoma. 
2012;53(8):1525–1529.  
82. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple 
myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 
2005;105(11):4532–4539.  
83. Ladetto M, Ferrero S, Drandi D, et al. Prospective molecular monitoring of minimal residual disease after non-
myeloablative allografting in newly diagnosed multiple myeloma. Leukemia. 2016;30(5):1211–1214.  
84. Passera R, Pollichieni S, Brunello L, et al. Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in 
Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. Biol Blood Marrow Transplant. 
2013;19(6):940–948.  
85. Donato ML, Siegel DS, Vesole DH, et al. The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but 
21 
Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic 
Transplantation. Biol Blood Marrow Transplant. 2014;20(8):1211–1216.  
86. Michallet M, Sobh M, El-Cheikh J, et al. Evolving strategies with immunomodulating drugs and tandem 
autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp 
Hematol. 2013;41(12):1008–1015.  
87. Caballero-Velázquez T, López-Corral L, Encinas C, et al. Phase II clinical trial for the evaluation of bortezomib within 
the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. 
Br J Haematol. 2013;162(4):474–482.  
88. Kröger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide 
maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 
2013;48(3):403–407.  
89. Kneppers E, van der Holt B, Kersten M-J, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem 
cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413–
2419.  
90. Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic 
hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183–1189.  
91. Htut M, D’Souza A, Bruno B, et al. Survival after Relapse Following Tandem Allogeneic Vs. Tandem Autologous 
Hematopoietic Cell Transplantation (HCT) for Myeloma (MM). Blood. 2016;128(22):833.  
92. Giaccone L, Evangelista A, Patriarca F, et al. Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo 
Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood. 2016;128(22):3469.  
93. López Corral L, Caballero Velázquez T, López Godino O, et al. Response to Proteosome Inhibitors and 
Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long 
Term Follow up Study. Blood. 2016;128(22):3436.  
94. LeBlanc R, Ahmad I, Terra R, et al. Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell 
Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk 
Multiple Myeloma Patients. Blood. 2016;128(22):2306.  
95. Klyuchnikov E, von Pein U-M, Ayuk FA, et al. Daratumumab Is an Effective and Safe Salvage Therapy in 
Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. Blood. 
2016;128(22):3437.  
96. Cook G, Carter CR, Brock K, et al. Immune Biomarkers Identify Sustained Quantitative and Functional Immune 
Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. 
Blood. 2016;128(22):4585.  
97. McKiernan P, Siegel DS, Vesole DH, et al. Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma 
Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings. 
Blood. 2016;128(22):2302.  
98. Patriarca F, Giaccone L, Onida F, et al. New drugs and allogeneic hematopoietic stem cell transplantation for 
hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 
Expert Opin. Biol. Ther. 2017;17(7):821–836.  
99. Ludwig H, Weisel K, Petrucci MT, et al. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with 
bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia. 2017;31(4):997–
1000.  
100. Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Is immunotherapy here to stay in multiple 
myeloma? Haematologica. 2017;102(3):423–432.  
101. Garfall AL, Maus M V, Hwang W-T, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N 
22 
Engl J Med. 2015;373(11):1040–1047.  
102. Suck G, Odendahl M, Nowakowska P, et al. NK-92: an “off-the-shelf therapeutic” for adoptive natural killer cell-based 
cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485–492.  
103. Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation 
and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310.  
104. Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187–
1199.  
105. Yang J, Zhu H, Tan Z, et al. Comparison of two functional kappa light-chain transcripts amplified from a hybridoma. 
Biotechnol Appl Biochem. 2013;60(3):289–297.  
106. Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells 
enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–927.  
107. Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against 
acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–3472.  
108. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 
2016;127(26):3321–3330.  
109. Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells 
enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–927.  
110. Engelhardt M, Ihorst G, Caers J, Gunther A, Wasch R. Autotransplants in older multiple myeloma patients: hype or 
hope in the era of novel agents? Haematologica. 2016;101(11):1276–1278.  
111. Karlin L, Arnulf B, Chevret S, et al. Tandem autologous non-myeloablative allogeneic transplantation in patients with 
multiple myeloma relapsing after a first high dose therapy. Bone Marrow Transplant. 2011;46(2):250–256.  
112. Bashir Q, Khan H, Orlowski RZ, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell 
transplantation for multiple myeloma. Am J Hematol. 2012;87(3):272–276.  
113. Patriarca F, Einsele H, Spina F, et al. Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after 
Autograft: A Multicenter Retrospective Study Based on Donor Availability. Biol Blood Marrow Transplant. 
2012;18(4):617–626.  
114. Wirk B, Byrne M, Dai Y, Moreb JS. Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell 
Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation. J Clin 
Med Res. 2013;5(3):174-184. 
115. Freytes CO, Vesole DH, LeRademacher J, et al. Second transplants for multiple myeloma relapsing after a previous 
autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014;49(3):416–
421.  
116. Klyuchnikov E, Wolschke C, Badbaran A, et al. Allogeneic Stem Cell Transplantation As Salvage Therapy for First 
Relapse after Autografting in Multiple Myeloma Patients. Blood. 2016;128(22):4619.  
 
23 
TABLE 1. EFFICACY OF SEQUENTIAL APPROACHES WITH AUTOLOGOUS TRANSPLANTATION: IMPROVEMENT IN RESPONSE RATES, 
PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL WITH SEQUENTIAL INDUCTION, TRANSPLANT, AND CONSOLIDATION-
MAINTENANCE REGIMENS 
REGIMEN N of 
patients 
MEDIAN FU (months) CR (%) PFS OS REF 
PAD 
MEL 200 
V maintenance 
 
413 
 
41 
7 
21 
36 
 
50% at 35 months 
 
61% at 60 months 
 
4 
VTD 
MEL 200 
VTD consolidation 
 
236 
 
43 
23 
49 
61 
 
60% at 36 months* 
 
90% at 36 months* 
 
28 
VTD 
MEL 200 
T/INF/VT maintenance 
 
130 
 
35 
35 
46 
- 
 
50% at 56 months 
 
74% at 48 months 
 
6 
VRD 
MEL 200 
VRD consolidation 
R maintenance 
 
350 
 
39 
- 
59° 
- 
- 
 
50% at 50 months 
 
81% at 48 months 
 
10 
VCD 
MEL 200 
VRD/NO consolidation 
R maintenance 
 
1499 
 
53 
- 
32 
- 
- 
 
65% at 36 months 
 
86% at 36 months 
 
21 
KRD 
MEL200 
KRD consolidation 
R maintenance 
 
46 
 
17 
24 
41 
61 
- 
 
91% at 24 months 
 
- 
 
13 
IRD 
MEL200 
 
42 
 
20 
12 
17 
 
83% at 20 months 
 
95% at 20 months 
 
11 
24 
Abbreviations: CR, complete response; MEL 200: melphalan 200 mg/m2,; PFS, progression-free survival; OS, overall survival; FU: follow-up; R, lenalidomide; RP, lenalidomide-prednisone; T, 
thalidomide; V, bortezomib; VTD, bortezomib-thalidomide-dexamethasone;; PAD, bortezomib-adriamycin-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-
cyclophosphamide-dexamethasone; KRD, carfilzomib-lenalidomide-dexamethasone; IRD, ixazomib-lenalidomide-dexamethasone; -, data not available ; °response to the overall treatment,*PFS/OS from 
the start of consolidation. 
 
 
 
 
 
 
IRD/IR consolidation 
I maintenance 
29/44 
- 
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TABLE 2. SAFETY (GRADE >3 ADVERSE EVENTS) OF SELECTED PRE-TRANSPLANT INDUCTION AND POST-TRANSPLANT 
CONSOLIDATION/MAINTENANCE REGIMENS 
 
 
REGIMEN NEUTROPENIA (%) 
THROMBOCYTOPENIA 
(%) 
ANEMIA 
(%) 
THROMBOEMBOLISM 
(%) 
PNP 
(%) 
INFECTION 
(%) REF 
INDUCTION  
PAD 3 10 8 4 24 26 4 
VTD 10 8 - 12 14 21 6 
VCD 35° 4 6 3# 8# 22# 5 
KRD 16 2 2 - - 15 13 
CONSOLIDATION 
VTD - 5* - 1 1 1 28 
KRD 26 15 - - - 2 13 
MAINTENANCE 
V  0 4 1 1 5 24 4 
T 1-16 2 1 1 8-14 18 4,33 
R  23-51 4-14 2-5 2-3 1 6-8 19,20,34,35 
TV 13 10 - - 15 - 33 
Abbreviations: R, lenalidomide; T, thalidomide; V, bortezomib;  VTD, bortezomib-thalidomide-dexamethasone; PAD, bortezomib-adryamicin-dexamethason; VRD, bortezomib-
lenalidomide-dexamethasone; VCD, bortezomib-cyclophosfamide-dexamethasone; KRD, carfilzomib-lenalidomide-dexamethasone; IRD, ixazomib-lenalidomide-dexamethasone; 
RD, lenalidomide-dexamethasone; TV, thalidomide-bortezomib; PNP: peripheral neuropathy; °including leukopenia; #≥grade 2; * all grade events;  -  Data not available 
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Table 3. RECOMMENDATIONS FOR UPFRONT TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS. 
 Regimens Recommendation Rationale for recommendation 
Induction VTD (1A) 
VRD (1B) 
PAD (1A) 
VCD (1B)  
 
Treatment choice: 
-Non-neurotoxic agents 
(doxorubicin, lenalidomide, 
cyclophosphamide) preferred 
in pts with PNP 
- Non-thrombotic agents 
(cyclophosphamide) to be 
considered in pts with 
thrombosis  
- Lenalidomide use is 
supported by better toxicity 
profile than thalidomide, and 
the advantage of an oral use 
as compared with doxorubicin. 
 
Number of cycles: 
- treatment should be 
continued for at least 3-4 
cycles with all regimens 
- patients achieving >PR with 
VTD can continue for another 
2 cycles 
 
Treatment choice: 
- Randomized comparisons showing the superiority of one of these regimens over 
the others are lacking. 
- Treatment choice should consider patient characteristics and expected toxicity of 
the proposed regimens. 
- VTD showed superiority vs TD, chemotherapy without novel agents and VCD.6,7,8 
- VRD showed promising phase II and III efficacy results, with a good safety profile, 
but randomized comparisons VRD vs other induction regimens are lacking.9,10 
 
 
 
 
 
Number of cycles: 
- Most of the trials evaluated 3-4 cycles of induction 
- Phase III data on efficacy and toxicities of > 4 cycles are lacking, except for VTD. 
4,5,6,7,8
  
- Randomized comparison of prolonged induction until best response and ASCT vs 
fixed duration of induction and ASCT are lacking  
Transplant MEL200 (1A) Treatment choice:  
MEL200  
 
 
 
Number of cycles: 
2 MEL200-ASCT are 
recommended in particular in 
patients with high-risk disease 
and <CR 
 
 
 
 
1 MEL200-ASCT can be 
considered for standard risk 
patients achieving >VGPR 
Treatment choice: 
- Randomized trials showed a favourable efficacy and safety profile of MEL200 vs 
other regimens (Bu/Mel, Ida/Mel/Cy, BCNU/Etoposide/Mel, Mel100, Mel140).18 
- Novel agents in the conditioning regimens were evaluated so far only in single arm 
studies. 18 
 
Number of cycles: 
- Data from meta-analysis and 2 phase III trials  suggest that the greatest benefit 
with double vs single ASCT is for patients with high-risk disease.4,24,25 Phase III data 
of STAMINA trial, showed equal PFS between patients that, after a first ASCT, were 
randomized to consolidation with a second ASCT plus lenalidomide maintenance, or 
VRD consolidation -followed by maintenance or maintenance only, but these results 
may be affected by non-adherence to the second transplant policy in 30% of 
patients. maintenance4,26 
 
- Integrated patient level meta-analysis in the context of bortezomib induction 
showed the greatest benefit for double vs single ASCT in patients who failed CR to 
27 
induction therapy. Before novel agent treatment, the benefit of double ASCT was 
reported in patients achieving <VGPR after the first ASCT.23 
Consolidation VTD (2A) 
VRD (2A) 
Treatment choice: 
- Lenalidomide use is 
supported by a better toxicity 
profile than thalidomide 
- Lenalidomide should be 
preferred in pts with PNP 
 
 
Duration of therapy: 
- 2 VTD cycles  
 
- 2 VRD cycles 
 
Treatment choice: 
- Randomized comparisons showing the superiority of one of the regimens over the 
other are lacking. 
- Treatment choice should consider patient characteristics and expected toxicity of 
the proposed regimen 
 
 
 
Duration of therapy: 
- A randomized trial showed the superiority of 2 VTD vs 2 TD consolidation in terms 
of response rate and PFS7 
- Preliminary data of a randomized trial showed the superiority of 2 VRD cycles vs 
no consolidation in terms of PFS29 
 
Maintenance Lenalidomide 
(1A) 
Thalidomide (1A) 
Bortezomib (1B) 
Treatment choice: 
- Lenalidomide use is 
supported by a better toxicity 
profile than thalidomide, 
which favours the long-term 
administration   
- Bortezomib use is supported 
by a better toxicity profile 
than thalidomide, and a 
potentially higher efficacy 
- IMIDs alone could be 
suboptimal in high-risk 
patients and patients with 
renal failure, who may benefit 
from bortezomib  
 
Duration of therapy: 
- Lenalidomide: at least 2 
years or until tolerated 
- Thalidomide: until tolerated 
- Bortezomib: 2 years 
Treatment choice: 
- Treatment choice should consider patient characteristics and expected toxicity of 
the proposed regimen 
- Thalidomide and lenalidomide maintenance have been evaluated in several 
trials19,30,31,34,35 
- One study showed the superiority of bortezomib over thalidomide maintenance, 
but results are limited by the fact that patients receiving bortezomib maintenance 
received bortezomib induction, while patients randomized to thalidomide received 
VAD 4 
- Randomized comparisons showing the superiority of lenalidomide vs 
thalidomide/bortezomib are lacking. 
- Subgroup analyses of randomized trials showed an uncertain benefit of IMiDs in 
patients with high-risk cytogenetics and renal failure, and a possible benefit with 
bortezomib. 30,31,4,35,37 
 
 
Duration of therapy: 
- there is no randomized trials comparing 2 years of lenalidomide vs lenalidomide 
until PD, but the median duration of maintenance is around 2 years in most of the 
trials 
- long term thalidomide use is limited by the poor tolerance (PNP) 
- bortezomib maintenance have been administered in clinical trials for up to 2 
years 
 
Abbreviations : MEL 200: melphalan 200 mg/m2,; ASCT, autologous stem cell transplant ; PFS, progression-free survival; OS, overall survival; VTD, bortezomib-thalidomide-dexamethasone;; PAD, 
bortezomib-adriamycin-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone; VAD, vincristine-doxorubicine-dexamethasone PNP, 
peropheral neuropathy ; IMiD, immunomodualtory drugs. 
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Table 4. RECOMMENDATIONS FOR TRANSPLANT IN ELDERLY PATIENTS AND PATIENTS WITH CO-MORBIDITIES. ALL 
RECOMMENDATIONS ARE LEVEL 2C. 
Factor to 
consider 
Cut-off for full-
dose Melphalan 
Recommendation Rationale for recommendation 
Age <65 years - Age should be considered not as single factor but 
together with Performance Status and co-morbidities 
(HCT-CI/MCI) 
- Biological rather than chronological age should be 
used in deciding eligibility to ASCT. 
- In patients between 65-70 years, with Karnofsky 
PS>90% and HCT-CI = 0 or R-MCI 0-3, it is reasonable 
to consider full dose Melphalan (200 mg/m2) 
- Based on biological age, melphalan dose reductions 
(Melphalan 100-140 mg/m2) can be appropriate. 
- Retrospective data showed in recent years no increase in 
TRM in elderly patients, probably due to better supportive 
measures and patient selection. These results have been 
achieved not only with reduced dose of Melphalan, but 
also with full dose.50–53,55–57 
Performance 
Status 
Karnofsky>90% - In patients with Karnofsky PS <90% Melphalan dose 
reductions (Melphalan 100-140 mg/m2) should be 
considered. 
 
- Full dose Melphalan (200 mg/mq) could be 
considered in patients with poor PS related to the MM, 
more than to other co-morbidities 
- Retrospective analysis of registry data showed an inferior 
OS in patients with Karnofsky PS<90%.41 
 
- Poor PS can be related to MM (i.e. bone disease, and rib 
and vertebral fractures that affect respiratory function, 
suboptimal response of MM to previous therapy can lead to 
anemia and fatigue). Achieving optimal disease control can 
improve patient PS.  
Co-
morbidities 
HCT-CI = 0 
R-MCI 0-3 
- In patients with HCT-CI >1 or R-MCI 4-6 Melphalan 
dose reductions (Melphalan 100-140 mg/m2) need to 
be considered. 
Specifically, in case of impaired:   
a) cardiac function (LVEF 40-50%; NYHA II) 
b) liver function (bilirubin >1.5 ULN, AST/ALT 
>2.5 ULN) 
c) pulmonary function (DLCO/FEV1 40-80%) 
d) renal function (GFR <60) 
but, in particular, for c) and d) a careful evaluation 
of the cause of impaired organ function should be 
done, and in case of impaired renal function related 
to MM, the risk benefit of full-dose Melphalan 
should be considered. 
- Retrospective analysis of registry data showed an inferior 
OS in patients with HCT-CI 1-2 or >2, even if TRM at 1 year 
was equivalent in HCT-CI 0 or >2.41 
-Retrospective data showed also inferior OS in patients with 
R-MCI >4 vs 0-3.43 
 
- Reduced organ function can be related to MM, in 
particular in case of renal failure and reduced pulmonary 
function due to bone fractures (thoracic cage).  Achieving 
optimal disease control can improve organ function, in 
particular in patients with renal failure, as shown in 
retrospective studies.49 
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TABLE 5. ALLOGENEIC STEM CELL TRANSPLANT UPFRONT, DONOR VS NO-DONOR PROSPECTIVE TRIALS 
 
STUDY DESIGN PATIENTS MEDIAN FU PFS OS REF 
High-risk patients: 
                          BU-FLU-ATG allo-SCT 
Auto-SCT  
                         2nd auto-SCT  
65 
 
219 
4.8 years 
Median 19% 
vs 
22% (p=0.58) 
Median 34%  
vs 
48% (p=0.07) 
67,68
 
                         FLU-MEL allo-SCT 
Auto-SCT <CR  
                          2nd auto-SCT 
25 
85 
5.2 years 
Median not reached  
vs 
31 months (p=0.08) 
Median not reached  
vs 
58 months (p=0.9) 
69
 
                          2Gy TBI allo-SCT 
Auto-SCT 
                          2nd Auto- SCT 
80 
 
82 
7 years 
Median 2.8 years 
vs 
2.4 years (p=0.005) 
Median not reached  
vs 
4.25 years 
(p=0.001) 
66,73
 
                         2Gy TBI allo-SCT 
Auto-SCT 
                         Auto-SCT +/-maintenance 
185 
 
397 
3.3 years 
At 3 years 43% 
vs 
46% (p=0.67) 
At 3 years 77% 
vs 
80% (p=0.191) 
70
 
                         2Gy TBI allo-SCT 
Auto-SCT 
                         maintenance T/IFN 
122* 
 
138 
6.4 years 
At 6 years 28% 
vs 
22% (p=0.19) 
At 6 years 55% 
vs 
55% (p=0.68) 
71
 
                         FLU-TBI allo- SCT 
Auto-SCT  
                         +/- 2nd auto-SCT  
91 
 
249 
8 years 
At 8 years 22%  
vs 
12% (p=0.027) 
At 8 years 49%  
vs 
36% (p=0.030) 
72,74
 
30 
Abbreviations: SCT, stem cell transplant;  BU, busulfan; FLU, fludarabine; ATG, anti-thymocyte globuline; MEL, melphalan; TBI, total body irradiation; T, thalidomide; IFN, 
interferon.   
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TABLE 6. ALLOGENEIC STEM CELL TRANSPLANT AT RELAPSE 
STUDY DESIGN PATIENTS MEDIAN FU PFS OS REF 
Tandem auto-allo-SCT at 
first relapse, retrospective 23 27 months Median 36.8 months 61 at 2 years 
111
 
Allo- SCT RIC and MAC, 
retrospective 149 (121 RIC) 28.5 months 15% at 5 years 21% at 5 years 
112
 
Donor vs No-Donor,  
retrospective  
75 donor (68 allo-
SCT) 
94 no donor  
19 months 
Donor 51% at 2 years 
No donor 53% at 2 
years p=0.32 
Donor 42% at 2 years 
No donor 18% at 2 
years p<0.0001 
113
 
First Relapse post auto-
SCT:  
allo-SCT vs 2nd auto-SCT, 
retrospective 
19 allo-SCT 
27 auto-SCT 
57 months from 
diagnosis 
Median 6 months 
Median 19 months 
p=0.56 
Median 19 months 
Median 27 months 
p=0.255 
114
 
First relapse: MAC + 
lenalidomide maintenance 33 19 months 52% at 3 years 79% at 3 years 
88 
RIC in relapse post auto-
SCT, retrospective 413 - Median 9.6 months Median 24 months 
77
 
First Relapse post auto:  
allo-SCT vs auto-SCT, 
retrospective 
152 allo-SCT 
137 auto-SCT 
30 months 
6% at 3 years 
12% at 3 years 
p=0.038 
20% at 3 years 
46% at 3 years 
p<0.001 
115
 
Allo-SCT at relapse, 
retrospective  
639 before 2004 
2766 after 2004 
36 months 
25% at 5 years 
33% at 5 years 
p<0.0001 
10% at 5 years 
15% at 5 years 
p<0.0001 
65
 
Allo-SCT at first relapse 
post auto-SCT, 
89 48 months 28% at 5 years 57% at 5 years 116 
32 
 
Abbreviations: SCT, stem cell transplant;  BU, busulfan; FLU, fludarabine; ATG, anti-thymocyte globuline; MEL, melphalan; TBI, total body irradiation; T, thalidomide; IFN, 
interferon. SCT, stem cell transplant;  RIC, reduced intensity conditioning; MAC myeloablative conditioning; EBMT, European Group for Blood and Marrow Transplantation;  
CIBMTR, Center for International Blood and Marrow Transplant Research 
* In 99 patients completing allo-SCT program there was a prolonged PFS compared to 155 completing the other arm (p=0.04) 
 
retrospective 
33 
Table 7. RECOMMENDATIONS FOR ALLOGRAFTING IN TRANSPLANT ELIGIBLE PATIENTS. 
 
 
Level of 
evidence 
Practical considerations Rationale for considerations 
At diagnosis - 
Clinical trial in young ultra high-risk/high-
risk patients  
 
Though results were discordant, prospective randomized studies (designed in the 
late ’90s – early 2000s) showed long-term disease control in subsets of patients 
who were not treated with new drugs; the combination of new drugs and graft-vs.-
myeloma may be of benefit in patients where prognosis remains currently very 
poor  
At relapse 2C 
Young patients with early relapse (18 
months) from first-line treatment 
with/without high-risk features   
Regardless of prognostic features, early relapse is overall associated with poor 
diagnosis. Retrospective studies support the existence of a potential benefit of 
graft-vs.-myeloma in this setting. The inclusion in control trials would be 
recommended 
 
Maintenance 
post allografting - 
Clinical Trial  Maintenance therapy is currently part of prospective trials open to accrual. 
Results are eagerly awaited 
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Figure Legend 
Figure 1. Recommended sequential treatment.  
Figure 2. Factors to consider for transplantation. 
 
 


 1 
Supplementary Table S1. GRADE recommendation for grading levels of evidence 
 
GRADE    
1 
Evidence strongly suggest that the benefit of 
the procedure out weights potential risks or 
risks of the procedures out weights potential 
benefit 
A 
Consistent evidence from systemic reviews 
of high-quality randomized studies or from 
high-quality randomized studies or from 
high-quality observational studies 
2 
Evidence suggests the benefit and risk of a 
procedure is finely balanced or uncertain 
B 
Evidence from randomized and 
observational studies with important 
methodological flaws 
  C 
Evidence from randomized and 
observational studies with major 
methodological flaws or other sources of 
evidence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Supplementary Table S2. Suggested Melphalan dose reduction in case of impaired organ function  
(Based on The Hematopoietic Cell Transplant-Comorbidity Index) 
 
Abbreviations: NYHA, New York Heart Association; DLCO, diffusion capacity of carbon monoxide; FEV1, forced expiratory volume; ULN, upper limit of normal; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase. 
 Full dose-melphalan (200 mg/sqm) Consider Reduced dose Melphalan (100-140 mg/sqm) 
Karnofsky Performance 
Status 
>90% 80-90% 
Cardiac Function  
Ejection Fraction 
NYHA <II 
>50% 
NYHA II, coronary artery disease, congestive heart failure, 
arrhythmias 
40%-50% 
Pulmonary Function  DLCO / FEV1 >80% DLCO/FEV1 65-80% 
Hepatic Function 
Bilirubin < ULN 
AST/ALT < ULN 
Bilirubin > ULN-1.5 x ULN 
AST/ALT > ULN-2.5xULN 
